Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report

Exec Edge

27 Mar

Visit Exec Edge Research for Full Report

By Exec Edge Research

Climb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.

As we highlighted in our 66-page initiation report last week (download here), CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy (MN), systemic lupus erythematosus and lupus nephritis (SLE/LN), and immune thrombocytopenia (ITP). The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.

Importantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.

Visit Exec Edge Research for Full Report

Executives-Edge.com

Rayk@capmarketsmedia.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2522359149"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522359149\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522359149?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-27 04:38","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2522359149","market":"nz","top_or_hot":-1,"title":"Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report","media":"Exec Edge","content":"<html><body><p><img height=\"533\" src=\"https://s.yimg.com/uu/api/res/1.2/ek1tHlISqTDMs3lK7cRFmg--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/exec_edge_220/a57d3f3d79919df2be9669d4d4605a19\" width=\"800\"/></p>\n<div>\n<div>\n<div>\n<form action=\"\" method=\"post\">\n<div>\n<span></span>\n<span></span>\n<span></span>\n</div>\n<div>\n<div>\n<div>\n<span><i></i></span>\n</div>\n<h2>Enter your email to download the full report</h2>\n<div>\n<div>\n<label for=\"stu_name\">Your Name</label>\n<input type=\"text\"/>\n</div>\n<div>\n<label for=\"stu_email\">Your Email</label>\n<input/>\n</div>\n</div>\n<div>\n<div>\n<label for=\"stu_custom_field_lPY9T\">Your Company</label>\n<input type=\"text\"/>\n</div>\n</div>\n<div>\n<input type=\"submit\" value=\"Submit\"/>\n</div>\n</div>\n</div>\n<span>\n<div>\n      Loading...\n     </div> </span>\n<div></div>\n</form>\n</div>\n</div>\n<div>\n<h1>Visit Exec Edge Research for Full Report</h1>\n</div>\n</div>\n<p>By Exec Edge Research</p>\n<p>Climb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.</p>\n<p>As we highlighted in our 66-page initiation report last week (<strong>download here</strong>), CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy (MN), systemic lupus erythematosus and lupus nephritis (SLE/LN), and immune thrombocytopenia (ITP). The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.</p>\n<p>Importantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.</p>\n<div>\n<div>\n<div>\n<form action=\"\" method=\"post\">\n<div>\n<span></span>\n<span></span>\n<span></span>\n</div>\n<div>\n<div>\n<div>\n<span><i></i></span>\n</div>\n<h2>Enter your email to download the full report</h2>\n<div>\n<div>\n<label for=\"stu_name\">Your Name</label>\n<input type=\"text\"/>\n</div>\n<div>\n<label for=\"stu_email\">Your Email</label>\n<input/>\n</div>\n</div>\n<div>\n<div>\n<label for=\"stu_custom_field_lPY9T\">Your Company</label>\n<input type=\"text\"/>\n</div>\n</div>\n<div>\n<input type=\"submit\" value=\"Submit\"/>\n</div>\n</div>\n</div>\n<span>\n<div>\n      Loading...\n     </div> </span>\n<div></div>\n</form>\n</div>\n</div>\n<div>\n<h1>Visit Exec Edge Research for Full Report</h1>\n</div>\n</div>\n<p>Executives-Edge.com</p>\n<p>Rayk@capmarketsmedia.com</p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClimb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-27 04:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/climb-bio-fueled-cash-poised-203855757.html><strong>Exec Edge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Enter your email to download the full report\n\n\nYour Name\n\n\n\nYour Email\n\n\n\n\n\nYour Company\n\n\n\n\n\n\n\n\n\n\n      Loading...\n      \n\n\n\n\n\nVisit Exec Edge Research for Full Report\n\n\nBy Exec Edge Research\nClimb ...</p>\n\n<a href=\"https://finance.yahoo.com/news/climb-bio-fueled-cash-poised-203855757.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://finance.yahoo.com/news/climb-bio-fueled-cash-poised-203855757.html","article_id":"2522359149","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522359149","pubTimestamp":1743021535,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Climb Bio, Inc.  reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.As we highlighted in our 66-page initiation report last week , CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy , systemic lupus erythematosus and lupus nephritis , and immune thrombocytopenia . The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.Importantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ITP":"IT科技包装","CLYM":"CLIMB BIO INC","BK4199":"纸制品"},"translate_title":"Climb Bio注入现金，准备在25季度更新报告中实现更多里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLYM":0.9,"ITP":1},"content_text":"Enter your email to download the full report\n\n\nYour Name\n\n\n\nYour Email\n\n\n\n\n\nYour Company\n\n\n\n\n\n\n\n\n\n\n      Loading...\n      \n\n\n\n\n\nVisit Exec Edge Research for Full Report\n\n\nBy Exec Edge Research\nClimb Bio, Inc. (Nasdaq: CLYM) reported full-year results, highlighting a healthy cash cushion and several milestones for investors to watch closely during the remainder of 2025.\nAs we highlighted in our 66-page initiation report last week (download here), CLYM’s lead asset is Budoprutug, an anti-CD19 monoclonal antibody engineered to target diseases such as membranous nephropathy (MN), systemic lupus erythematosus and lupus nephritis (SLE/LN), and immune thrombocytopenia (ITP). The company now has regulatory clearance from the FDA for clinical trials in all three of those indications and continues to strengthen the budoprutug IP. It has begun initiating clinical trials and expects to dose patients later this year.\nImportantly, CLYM has cash on its balance sheet totaling $212.5 million, up from $106.8 million as of the end of 2023. Per the management, these funds are expected to be sufficient to fund the company’s planned operations through 2027. Please click the link below to read the detailed quarterly update report.\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nEnter your email to download the full report\n\n\nYour Name\n\n\n\nYour Email\n\n\n\n\n\nYour Company\n\n\n\n\n\n\n\n\n\n\n      Loading...\n      \n\n\n\n\n\nVisit Exec Edge Research for Full Report\n\n\nExecutives-Edge.com\nRayk@capmarketsmedia.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}